Ever since the field-defining studies in Nature Medicine and the New England Journal demonstrated that cell therapies could hold lasting potential in lupus and beyond, the field has grown from strength to strength. With a surge of billion-dollar investments, the release of new groundbreaking data, and recent real-world clinical progression, the autoimmune cell therapy field is poised for clinical and commercial success.
The 3rd Cell Therapy for Autoimmune Disease Summit (December 2-4 | Philadelphia, PA) returns at a pivotal time, providing first-hand insights and case studies needed to keep your team ahead in this fast-evolving space. Reconnect with 130+ scientific pioneers, with expertise spanning CAR-T, Treg, in vivo and NK cell therapies, as they unveil the latest clinical data and cutting-edge innovations redefining the chronic care of autoimmune indications.
Access Your Brand-New 2025 Agenda Copy!
Learn directly from industry titans including Cabaletta Bio, Kyverna Therapeutics, Umoja Biopharma, Cartesian Therapeutics, Century Therapeutics, Artiva Biotherapeutics and Novartis, to benchmark your current strategies and gain a competitive edge amongst your peers to accelerate your lead candidate from preclinical innovation to clinical success.
Whether you are preparing for your first clinical trials, or making the transition into later phases, our carefully curated two-tracked agenda (now expanded to the Workshop Day!) has content tailored for you.
- Preclinical & Translational: Address challenges in antigen selection, delve into autologous and allogeneic translational strategies, and discuss alternatives to B-cell depletion, to bring the next wave of therapies to the clinic.
- Clinical: Unpack trial design, evaluate long-term clinical outcomes, share regulatory strategies, and learn how to operationalize studies for broader patient access.
With cell therapy companies increasingly targeting autoimmune diseases, and autoimmune companies continuing to embrace cellular approaches, ensure you join the industry’s definitive meeting committed to transforming the promise of cell therapies in autoimmunity into reality.